Type de document |
Article à caractère scientifique |
Auteurs |
Verger, P.; Saliba, B.; Rouillon, F.; Kovess, V.; Villani, P.; Bouvenot, G.; Lovell, A. M. |
Titre |
Determinants of co-prescription of anxiolytics with antidepressants in general practice |
Titre français |
Déterminants de la co-prescription d'anxiolytiques et d'antidépresseurs en médecine générale |
Année |
2008
|
Journal, volume, pages |
Canadian Journal of Psychiatry, 53, 2, 94-103 |
Résumé (anglais) |
Objectives: Anxiolytics are the most frequently prescribed psychotropic drugs in France. General
practitioners (GPs) tend to prescribe anxiolytics and other benzodiazepines to patients with major
depressive disorders (MDD). However, the extent to and reasons for which they prescribe these
medications together are not well documented. This article assesses how often and why GPs
coprescribe an anxiolytic when starting patients on antidepressant (AD) treatment, and which
patient- and GP-related factors are associated with this coprescription.
Methods: We used a survey of 131 GPs practising in southeastern France and of patients seen
consecutively during June to October 2004 to whom they prescribed an AD. Data were collected
from GPs (consultation-questionnaires focusing on their prescription, diagnosis, and symptom
detection) and patients (self-administered questionnaires, including the Hospital Anxiety and
Depression scale, and social and demographic characteristics). Factors associated with anxiolytic
coprescription were analyzed with a multilevel logistic regression.
Results: GPs completed 438 consultation-questionnaires for patients; 258 patients (58.9%)
returned their questionnaires. Sixty percent of the patients received anxiolytics with ADs.
Anxiolytics were prescribed more frequently by male GPs who reported feeling ill at ease treating
MDD, or detected suicidal ideation or anxiety in their patients, and finally to patients with stable
jobs.
Conclusions: Although some practice guidelines and authors acknowledge that there might be
some justification for coprescribing anxiolytics with ADs at the beginning of MDD treatment in
specific situations, the high percentage of coprescriptions for anxiolytics observed in our study
suggests that training and knowledge of GPs about MDD treatment are not optimal. |
Mots clés |
Anxiolytique; Connaissance; Etat dépressif; Médecin généraliste; Médicament psychotrope; Prescription; Recommandation |
Code |
08-S04 |
Accès au document | Commander le document |
